Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Neuroplasticidad en la enfermedad de Parkinson

29 de octubre de 2026 actualizado por: University of Minnesota

Plasticidad de los sistemas motores en la etapa temprana de la enfermedad de Parkinson

The purpose of this project is to increase our understanding of the early state and temporal evolution of neuroplastic changes in the cortex and subthalamic nucleus (STN) of people with PD, and the relationship of these changes to the emergence and expression of PD motor and non-motor signs. Neurophysiological biomarkers derived from this work may be important for the early detection and prediction of progression of disease. They can also provide the means to assess the efficacy of interventions designed to prevent or slow disease progression.

Descripción general del estudio

Descripción detallada

This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI), from Dr. Noam Harel's protocol IRB# STUDY00008096, and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function. The TMS experiment will use a Magstim Bistimn 2002 transcranial magnetic stimulation (TMS) unit and standard figure-of-eight coil (70 mm diameter) to deliver stimulation on the surface of the scalp. Stimulation will be delivered using either a single pulse or with a paired-pulse protocol (two stimuli, through the same TMS coil at inter-stimulus intervals of 50 or 80 ms). All surface EMG signals will be pre-amplified within the sensor and sent wirelessly via blue-tooth connection to a Delsys data collection system. Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function will used to assess behavioral status at baseline and 30-36 months later.

Tipo de estudio

De observación

Inscripción (Actual)

42

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • University of Minnesota

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

21 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

Adults diagnosed with Parkinson's Disease (early diagnosis, currently untreated) and age- and sex-matched healthy controls

Descripción

Inclusion Criteria:

Participants with PD

  • Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria
  • Not receiving levodopa or dopamine agonist to treat PD (at baseline)
  • Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters Healthy Controls
  • Age- (+/- 3 years) and sex-matched to participants with PD
  • Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters

Exclusion Criteria:

  • Dementia diagnosis and/or a University of California Brief Assessment of Capacity to Consent (UBACC) score and MacCAT-CR score indicating impaired capacity to consent
  • History of musculoskeletal disorders that significant affect movement of lower or upper limbs as determined at the time of enrollment
  • History of bipolar disorder, post-traumatic stress disorder or major depressive disorder
  • Other significant neurological disorders that may affect participation or performance in the study
  • Implanted DBS or other neurosurgeries to treat PD
  • Pregnancy

Additional exclusion criteria for TMS experiments (note that individuals who are excluded from the TMS experiment still have the opportunity to participate in the other data collection sessions):

  • History of seizures, epilepsy, stroke, multiple sclerosis, or traumatic brain injury
  • Recent history of frequent syncope (fainting) episodes in response to blood, emotional stress, or sensory triggers.
  • Intracranial metallic or magnetic devices (e.g. cochlear implant, deep brain stimulator)
  • Pacemaker or any implanted device
  • History of surgery on blood vessels, brain, or heart
  • Unexplained, recurring headaches or concussion within the last six months
  • Severe hearing impairment

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Early (untreated) Parkinson's Disease

Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria.

This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function.

Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function

Healthy Controls

Age- and sex-matched healthy controls.

This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function.

Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in volume of Subthalamic Nucleus
Periodo de tiempo: Baseline, 30-36 months

The volume of the subthalamic nucleus is assessed using MRI and reported in millimeters cubed (mm^3).

Baseline, 30-36 months
Change in fractional Anisotropy of Subthalamic Nucleus
Periodo de tiempo: Baseline, 30-36 months

Fractional anisotropy, measured using MRI, is a unit-less value between zero and one that describes the degree of anisotropy of water diffusion in a specified brain area. Higher values indicate a greater degree of anisotropy, while a score of zero indicates isotropic diffusion.

Baseline, 30-36 months
Change in cortico-STN Connectivity
Periodo de tiempo: Baseline, 30-36 months

Cortico-Subthalamic nucleus connectivity is measured using MRI and reported as a z score (unitless).

Baseline, 30-36 months
Change in paired Associative Stimulation-Motor Evoked Potential (PAS-MEP)
Periodo de tiempo: Baseline, 30-36 months

Motor evoked potential is measured as the amplitude of change in target muscle electrical activity following transcranial magnetic stimulation (TMS) and reported in units of millivolts (mV).

Baseline, 30-36 months
Change in Mattis Dementia Rating Scale 2 (DRS-2)
Periodo de tiempo: Baseline, 30-36 months

The DRS-2 consists of 24 items, rated on a scale from 0 to 6. Item scores are combined into five subscales: attention (8 items), initiation/perseveration (11 items), construction (6 items), conceptualization ( 6 items), and memory (5 items). These five subscale scores are summed to calculate a total score ranging from from 0 to 144 points, with lower scores indicating worse performance due to dementia.

Baseline, 30-36 months
Change in Rey Complex Figure and Matrix Reasoning of the Wechsler Adult Intelligence Scale - IV
Periodo de tiempo: Baseline, 30-36 months

Measure of visuospatial construction, memory and reasoning. Scaled score based on age norms.

Baseline, 30-36 months
Change in Stroop Color Word Test
Periodo de tiempo: Baseline, 30-36 months

Measure of response inhibition, selective attention and processing. Scaled score based on age norms.

Baseline, 30-36 months
Change in Wisconsin Card Sorting Test
Periodo de tiempo: Baseline, 30-36 months

Measures cognitive flexibility, abstract reasoning, and set-shifting. Scaled score based on age norms.

Baseline, 30-36 months
Change in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Subtest
Periodo de tiempo: Baseline, 30-36 months

Measures cognitive flexibility, abstract reasoning, and set-shifting. Scaled score based on age norms.

Baseline, 30-36 months
Change in Brief Visuospatial Memory Test - Revised (BVMT-R)
Periodo de tiempo: Baseline, 30-36 months

Measure of non-verbal (visuospatial) learning and memory abilities. Scaled score based on age norms.

Baseline, 30-36 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de marzo de 2021

Finalización primaria (Actual)

30 de junio de 2026

Finalización del estudio (Actual)

30 de junio de 2026

Fechas de registro del estudio

Enviado por primera vez

17 de febrero de 2022

Primero enviado que cumplió con los criterios de control de calidad

17 de marzo de 2022

Publicado por primera vez (Actual)

18 de marzo de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir